← Browse by Condition
Medical Condition
carcinoma ovarian epithelial
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 2
NCT04196257 Phase 1
Recruiting
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Enrollment
50 pts
Location
United States
Sponsor
Bio-Path Holdings, Inc.
NCT04519151 Phase 2
Recruiting
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Enrollment
24 pts
Location
Israel
Sponsor
Sheba Medical Center